Literature DB >> 7665994

Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.

J S Millar1, A H Lichtenstein, M Cuchel, G G Dolnikowski, D L Hachey, J S Cohn, E J Schaefer.   

Abstract

Levels of plasma very low density lipoprotein (VLDL) and low density lipoprotein (LDL) constituents increase with age. In an attempt to further define the mechanisms responsible for these changes, kinetic studies of VLDL and LDL apolipoprotein (apo) B-100 were carried out in 19 normolipidemic male subjects with plasma total cholesterol and triglyceride levels below the 90th percentile whose ages ranged from 24 to 73 years. Subjects were maintained on standardized diets consisting of 47-49% of calories as carbohydrate, 15% protein, and 36-40% fat (15-17% saturated, 15-17% monounsaturated, 6% polyunsaturated) with 150 mg cholesterol/1000 kcal. At the end of the diet period, the metabolism of apoB-100 within VLDL, intermediate density lipoprotein (IDL), and LDL was studied in the fed state using a primed-constant infusion of [2H3]leucine. Data were fit to a multicompartmental model to determine residence times and production rates of apoB-100 in each fraction. There were significant positive correlations between age and VLDL, IDL, and LDL apoB-100 concentrations (r = 0.50, 0.62, and 0.69; P = 0.03, 0.004, and 0.001, respectively). There was a positive correlation between age and the production rate of VLDL apoB-100 (r = 0.50, P = 0.03), but there was no significant relationship between age and either IDL or LDL apoB-100 production rates. Age was also positively correlated with the residence time of LDL apoB-100 (r = 0.68 P = 0.001). Our data suggest that the age-associated increase in VLDL apoB-100 is due to an increased production rate of this constituent, whereas the age-associated increase in LDL apoB-100 is due to an increased residence time of these particles in plasma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665994

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  17 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 2.  Biomarkers related to aging in human populations.

Authors:  Eileen Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Dawn Alley
Journal:  Adv Clin Chem       Date:  2008       Impact factor: 5.394

3.  Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study.

Authors:  Masumi Ai; Seiko Otokozawa; Bela F Asztalos; Yasuki Ito; Katsuyuki Nakajima; Charles C White; L Adrienne Cupples; Peter W Wilson; Ernst J Schaefer
Journal:  Clin Chem       Date:  2010-04-29       Impact factor: 8.327

4.  Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women.

Authors:  Stefania Lamon-Fava; Borbala Postfai; Margaret Diffenderfer; Carl DeLuca; John O'Connor; Francine K Welty; Gregory G Dolnikowski; P Hugh R Barrett; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-12-08       Impact factor: 8.311

5.  Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin.

Authors:  Raul D Santos; Ana P M Chacra; Aleksandra Morikawa; Carmen C Vinagre; Raul C Maranhão
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

6.  Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men.

Authors:  L Duvillard; E Florentin; M L Lalanne-Mistrich; J M Petit; S Baillot-Rudoni; A Brun-Pacaud; J M Brun; P Gambert; B Vergès
Journal:  Diabetologia       Date:  2005-05-26       Impact factor: 10.122

7.  Plasma kinetics of a cholesterol-rich emulsion in young, middle-aged, and elderly subjects.

Authors:  L B Pinto; M Wajngarten; E L Silva; C C Vinagre; R C Maranhão
Journal:  Lipids       Date:  2001-12       Impact factor: 1.880

8.  Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

Authors:  John S Millar; Danielle Duffy; Ramprasad Gadi; LeAnne T Bloedon; Richard L Dunbar; Megan L Wolfe; Rajesh Movva; Ashish Shah; Ilia V Fuki; Mary McCoy; Cynthia J Harris; Ming-Dauh Wang; Daniel C Howey; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-06       Impact factor: 8.311

Review 9.  Clinical considerations and mechanistic determinants of postprandial lipemia in older adults.

Authors:  Christos S Katsanos
Journal:  Adv Nutr       Date:  2014-05-14       Impact factor: 8.701

10.  Gender-specific differences in the kinetics of nonfasting TRL, IDL, and LDL apolipoprotein B-100 in men and premenopausal women.

Authors:  Nirupa R Matthan; Susan M Jalbert; P Hugh R Barrett; Gregory G Dolnikowski; Ernst J Schaefer; Alice H Lichtenstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-24       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.